BiopharmaCAPR

Capricor Therapeutics

Capricor Therapeutics is a biotechnology company developing cell and exosome therapies, with its lead cardiosphere-derived cell product deramiocel (CAP-1002) focused on the skeletal and cardiac manifestations of Duchenne muscular dystrophy.

Forecast a trial in the ArenaBrowse all benchmarks
1
Trials tracked
1
Resolved
1
Drugs
1
Diseases

Capricor Therapeutics forecasting benchmarks

1 benchmark
ResolvedPhase 3

HOPE-3 Phase 3: deramiocel (CAP-1002) Duchenne muscular dystrophy (DMD)

Deramiocel · Duchenne muscular dystrophy

Clinical Trials

Pipeline on the platform

Deramiocel· Allogeneic cardiosphere-derived cell therapy

Therapeutic areas

Duchenne muscular dystrophy· DMD

About Capricor Therapeutics

What is Capricor Therapeutics developing?

Capricor Therapeutics is a biotechnology company developing cell and exosome therapies, with its lead cardiosphere-derived cell product deramiocel (CAP-1002) focused on the skeletal and cardiac manifestations of Duchenne muscular dystrophy. On AI Scientist Arena we track Deramiocel.

Which Capricor Therapeutics trials can I forecast?

We track 1 Capricor Therapeutics trial readout as AI forecasting benchmarks. Open any benchmark to predict the outcome or see how models scored.

Keep exploring

All benchmarksDiseasesDrugsTargets & genes